pharmaphorum Podcast

The pharmaphorum podcast’s first episode of 2019 features Professor Brian D Smith on what makes a modern, and successful, medical marketing team.

He spoke to Dominic Tyer about his fascinating work on pharma’s DNA and evolutionary trends within the industry, before drilling down into how it can be applied to pharmaceutical marketing.

Brian D Smith

A leading authority on the evolution of the life sciences industry, with a 40-year career that has seen him move from research to marketing to academia, Prof Smith has published over 300 books, papers and articles on the topic, including The Future of Pharma, Darwin’s Medicine and Brand Therapy.

He is currently a visiting professor at the University of Hertfordshire, adjunct professor at Milan’s SDA Bocconi School of Management and principle advisor at Pragmedic.

You can listen to episode 6 of the pharmaphorum podcast in the player below, download the episode to your computer or find it – and subscribe to the rest of the series – in iTunes and Spotify.

The pharmaphorum podcast’s first episode of 2019 features Professor Brian D Smith on what makes a modern, and successful, medical marketing team.

For episode 5 of the pharmaphorum podcast Dominic Tyer met Blueberry Therapeutics’ CEO Dr John Ridden at The Wellcome Collection in London to talk about the UK biotech he co-founded, its strategy and bringing innovation to life through Blueberry’s nanomedicine approach.

Also on the agenda for the podcast was Blueberry Therapeutics’ focus on dermatology, a recent funding deal it signed with China Medical Venture Investment and the concept of risk management for a small biotech company.

Dr John Ridden

Prior to co-founding Blueberry Therapeutics, which is based at AstraZeneca’s former Alderley Park site, he spent 11 years at that pharmaceutical company in senior leadership roles in target identification and translational research, working across the areas of oncology, respiratory, inflammation and cardiovascular.

Before joining AstraZeneca John spent seven years at Pfizer, leading a number of cardiovascular and tissue repair drug discovery projects, and ahead of that spent time at a small UK biotech company.

You can listen to episode 5 of the pharmaphorum podcast in the player below, download the episode to your computer or find it – and subscribe to the series – in iTunes.

For episode 5 of the pharmaphorum podcast Dominic Tyer met Blueberry Therapeutics’ CEO Dr John Ridden at The Wellcome Collection in London to talk about the UK biotech he co-founded, its strategy and bringing innovation to life through Blueberry’s nanomedicine approach.

For episode 5 of the pharmaphorum podcast Dominic Tyer met Blueberry Therapeutics’ CEO Dr John Ridden at The Wellcome Collection in London to talk about the UK biotech he co-founded, its strategy and bringing innovation to life through Blueberry’s nanomedicine approach.

Also on the agenda for the podcast was Blueberry Therapeutics’ focus on dermatology, a recent funding deal it signed with China Medical Venture Investment and the concept of risk management for a small biotech company.

Dr John Ridden

Prior to co-founding Blueberry Therapeutics, which is based at AstraZeneca’s former Alderley Park site, he spent 11 years at that pharmaceutical company in senior leadership roles in target identification and translational research, working across the areas of oncology, respiratory, inflammation and cardiovascular.

Before joining AstraZeneca John spent seven years at Pfizer, leading a number of cardiovascular and tissue repair drug discovery projects, and ahead of that spent time at a small UK biotech company.

You can listen to episode 5 of the pharmaphorum podcast in the player below, download the episode to your computer or find it – and subscribe to the series – in iTunes.

In episode 4 of the podcast pharmaphorum talked to Dr Joe Wiley, CEO of UK-based biopharmaceutical company Amryt Pharma, about its strategy and work in the rare diseases and gene therapy space.

Before co-founding Amryt Pharma in 2015, Joe’s 20-year career spanned the pharmaceutical, medical and venture captial industries, and included time as Astellas Pharma’s medical director and investment roles at Spirit Capital.

He talked to Dominic Tyer about Amryt’s busy year of milestones in 2018 and what the future holds for the young biopharmaceutical company.

Dr Joe Wiley

Alongside discussing the company’s strategy to commercialise treatments for rare and ultra-rare conditions, he also shared details of a fascinating clinical trial data collaboration with Amicus focusing on the greater patient good.

You can listen to episode 4 of the pharmaphorum podcast in the player below, download the episode to your computer or find it – and subscribe to the series – in iTunes.

In episode 4 of the podcast pharmaphorum talked to Dr Joe Wiley, CEO of UK-based biopharmaceutical company Amryt Pharma, about its strategy and work in the rare diseases and gene therapy space.

In episode 4 of the podcast pharmaphorum talked to Dr Joe Wiley, CEO of UK-based biopharmaceutical company Amryt Pharma, about its strategy and work in the rare diseases and gene therapy space.

Before co-founding Amryt Pharma in 2015, Joe’s 20-year career spanned the pharmaceutical, medical and venture captial industries, and included time as Astellas Pharma’s medical director and investment roles at Spirit Capital.

He talked to Dominic Tyer about Amryt’s busy year of milestones in 2018 and what the future holds for the young biopharmaceutical company.

Dr Joe Wiley

Alongside discussing the company’s strategy to commercialise treatments for rare and ultra-rare conditions, he also shared details of a fascinating clinical trial data collaboration with Amicus focusing on the greater patient good.

You can listen to episode 4 of the pharmaphorum podcast in the player below, download the episode to your computer or find it – and subscribe to the series – in iTunes.

For episode 3 of the pharmaphorum podcast Dominic Tyer went to the UK headquarters of Sandoz to meet the head of the company’s UK specialty business Kavya Gopal.

There, they spoke about the current state of play in biosimilars and looked ahead to how the landscape will evolve in the future, given the medicines’ consistently rising profile in recent years.

Kavya Gopal

Despite this, it’s only in the last 12 months or so, with the approval of the first cancer and then arthritis biosimilars, that this type of medicine has really started to come to the fore.

As specialty business head for Sandoz UK, not to mention chair of the British Biosimilars Association, Kavya had a wealth of knowledge to share during a discussion that encompassed market developments, policy learnings and pressure points within the regulatory process.

She also talked about market access for biosimilars, variation in biosimilar prescribing and why the medicines matter to cash-strapped healthcare systems, such as the UK’s NHS.

You can listen to episode 3 of the pharmaphorum podcast in the player below, download the episode to your computer or find it – and subscribe to the series – in iTunes.

For episode 3 of the pharmaphorum podcast Dominic Tyer went to the UK headquarters of Sandoz to meet the head of the company’s UK specialty business Kavya Gopal.

There, they spoke about the current state of play in biosimilars and looked ahead to how the landscape will evolve in the future, given the medicines’ consistently rising profile in recent years.

Kavya Gopal

Despite this, it’s only in the last 12 months or so, with the approval of the first cancer and then arthritis biosimilars, that this type of medicine has really started to come to the fore.

As specialty business head for Sandoz UK, not to mention chair of the British Biosimilars Association, Kavya had a wealth of knowledge to share during a discussion that encompassed market developments, policy learnings and pressure points within the regulatory process.

She also talked about market access for biosimilars, variation in biosimilar prescribing and why the medicines matter to cash-strapped healthcare systems, such as the UK’s NHS.

You can listen to episode 3 of the pharmaphorum podcast in the player below, download the episode to your computer or find it – and subscribe to the series – in iTunes.